Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2018 16:37 ET | Source: BioDelivery Sciences International, Inc.

CORRECTING and REPLACING -- BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

In a release issued under the same headline earlier today by BioDelivery Sciences International, Inc. (NASDAQ:BDSI), please note that in the second bullet of the Corporate section, the end date of the...
March 15, 2018 16:01 ET | Source: BioDelivery Sciences International, Inc.

BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

Full-year 2017 net revenue of $62.0 million vs. $15.5 million in 2016 BELBUCA® fourth quarter 2017 net revenue of $9.4 million vs. $6.4 million in third quarter; an increase of 47% ...
March 14, 2018 07:00 ET | Source: BioDelivery Sciences International, Inc.

BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference

RALEIGH, N.C., March 14, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
March 08, 2018 16:15 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results

PHOENIX, March 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
March 07, 2018 07:00 ET | Source: BioDelivery Sciences International, Inc.

BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2017 Financial Results on Thursday, March 15

RALEIGH, N.C., March 07, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
March 05, 2018 07:00 ET | Source: BioDelivery Sciences International, Inc.

BioDelivery Sciences to Present at the 30th Annual ROTH Conference

RALEIGH, N.C., March 05, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
February 22, 2018 08:00 ET | Source: Aegis Therapeutics LLC

Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications

SAN DIEGO, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,895,444 providing non-invasive metered nasal spray delivery of multiple...
February 09, 2018 04:26 ET | Source: TheRecover.com

Medically Assisted Sobriety Can Addicts Be Considered Sober?

SAN DIEGO, Feb. 09, 2018 (GLOBE NEWSWIRE) -- A new article released by The Recover offers insight about the stigma surrounding Medication assisted treatments, a now growing and widely used method...
February 06, 2018 07:00 ET | Source: BioDelivery Sciences International, Inc.

BioDelivery Sciences Announces BELBUCA® Patent Litigation Settlement Agreement with Teva

RALEIGH, N.C., Feb. 06, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA,...
January 30, 2018 08:00 ET | Source: BioDelivery Sciences International, Inc.

BioDelivery Sciences Announces Launch and Availability of BELBUCA® in Canada

RALEIGH, N.C., Jan. 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) and Purdue Pharma (Canada) announced today that BELBUCA® (buprenorphine) buccal...